
Company expands AI/ML driven capabilities to pursue novel biomarker discovery to predict patient outcomes and drug response in oncology. Read our white paper below that details the multi-year study conducted with UPMC Magee-Women’s Hospital.
Company expands AI/ML driven capabilities to pursue novel biomarker discovery to predict patient outcomes and drug response in oncology. Read our white paper below that details the multi-year study conducted with UPMC Magee-Women’s Hospital.
Drug repurposing using the Predictive Oncology machine learning approach and proprietary biobank of frozen dissociated tumor cells (DTCs) is outlined in this new white paper.
Following the generation of successful results with the University of Michigan through the ACE program, Predictive Oncology is now actively calling for submissions for a